Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: Which scoring system should we use?

Young Su Park, Hee Sang Hwang, Hye Jin Park, Min Hee Ryu, Heung Moon Chang, Jeong Hwan Yook, Byung Sik Kim, Se Jin Jang, Yoon Koo Kang

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

It has been reported that HER2 expression is different in gastric and breast cancers, and a gastric cancer scoring system (GCSS) has recently been suggested. We investigated HER2 protein expression using GCSS and a breast cancer scoring system (BCSS) and correlated it with HER2 gene amplification. HER2 status was evaluated in 1091 cases by analyzing tissue microarrays constructed using 2 different cores from each case. Polyclonal (HercepTest) and monoclonal (Pathway) antibodies were used for immunohistochemistry (IHC), and results were scored by BCSS and GCSS. Gene amplification was evaluated by automated dual-color silver-enhanced in situ hybridization (SISH) in all cases and correlated with the results from fluorescence in situ hybridization (FISH) in 590 cases. The concordance between the IHC results using polyclonal and monoclonal antibodies was high (κ = 0.785). The results of dual-color SISH and FISH showed very high concordance as well (κ = 0.918). GCSS was significantly more sensitive for detecting SISH positivity than was BCSS in both antibodies (polyclonal, P =.003; monoclonal, P <.001), but specificity was higher in BCSS than GCSS (polyclonal, P =.004; monoclonal, P <.001). It has been recently shown that HER2-overexpressing patients with unresectable gastric cancer benefited from trastuzumab therapy. Because IHC is recommended before gene amplification studies in HER2 testing, GCSS should be used for evaluating HER2 expression in gastric cancers.

Original languageEnglish
Pages (from-to)413-422
Number of pages10
JournalHuman Pathology
Volume43
Issue number3
DOIs
StatePublished - 1 Mar 2012

Fingerprint

erbB-2 Genes
Gene Amplification
Stomach Neoplasms
In Situ Hybridization
Immunohistochemistry
Breast Neoplasms
Silver
Fluorescence In Situ Hybridization
Color
Monoclonal Antibodies

Keywords

  • Gastric Cancer
  • HER2
  • Immunohistochemistry
  • In situ hybridization
  • Sensitivity
  • Specificity

Cite this

Park, Young Su ; Hwang, Hee Sang ; Park, Hye Jin ; Ryu, Min Hee ; Chang, Heung Moon ; Yook, Jeong Hwan ; Kim, Byung Sik ; Jang, Se Jin ; Kang, Yoon Koo. / Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization : Which scoring system should we use?. In: Human Pathology. 2012 ; Vol. 43, No. 3. pp. 413-422.
@article{b44983e5ca2a44638d12e812125eadb3,
title = "Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: Which scoring system should we use?",
abstract = "It has been reported that HER2 expression is different in gastric and breast cancers, and a gastric cancer scoring system (GCSS) has recently been suggested. We investigated HER2 protein expression using GCSS and a breast cancer scoring system (BCSS) and correlated it with HER2 gene amplification. HER2 status was evaluated in 1091 cases by analyzing tissue microarrays constructed using 2 different cores from each case. Polyclonal (HercepTest) and monoclonal (Pathway) antibodies were used for immunohistochemistry (IHC), and results were scored by BCSS and GCSS. Gene amplification was evaluated by automated dual-color silver-enhanced in situ hybridization (SISH) in all cases and correlated with the results from fluorescence in situ hybridization (FISH) in 590 cases. The concordance between the IHC results using polyclonal and monoclonal antibodies was high (κ = 0.785). The results of dual-color SISH and FISH showed very high concordance as well (κ = 0.918). GCSS was significantly more sensitive for detecting SISH positivity than was BCSS in both antibodies (polyclonal, P =.003; monoclonal, P <.001), but specificity was higher in BCSS than GCSS (polyclonal, P =.004; monoclonal, P <.001). It has been recently shown that HER2-overexpressing patients with unresectable gastric cancer benefited from trastuzumab therapy. Because IHC is recommended before gene amplification studies in HER2 testing, GCSS should be used for evaluating HER2 expression in gastric cancers.",
keywords = "Gastric Cancer, HER2, Immunohistochemistry, In situ hybridization, Sensitivity, Specificity",
author = "Park, {Young Su} and Hwang, {Hee Sang} and Park, {Hye Jin} and Ryu, {Min Hee} and Chang, {Heung Moon} and Yook, {Jeong Hwan} and Kim, {Byung Sik} and Jang, {Se Jin} and Kang, {Yoon Koo}",
year = "2012",
month = "3",
day = "1",
doi = "10.1016/j.humpath.2011.05.019",
language = "English",
volume = "43",
pages = "413--422",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "3",

}

Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization : Which scoring system should we use? / Park, Young Su; Hwang, Hee Sang; Park, Hye Jin; Ryu, Min Hee; Chang, Heung Moon; Yook, Jeong Hwan; Kim, Byung Sik; Jang, Se Jin; Kang, Yoon Koo.

In: Human Pathology, Vol. 43, No. 3, 01.03.2012, p. 413-422.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization

T2 - Which scoring system should we use?

AU - Park, Young Su

AU - Hwang, Hee Sang

AU - Park, Hye Jin

AU - Ryu, Min Hee

AU - Chang, Heung Moon

AU - Yook, Jeong Hwan

AU - Kim, Byung Sik

AU - Jang, Se Jin

AU - Kang, Yoon Koo

PY - 2012/3/1

Y1 - 2012/3/1

N2 - It has been reported that HER2 expression is different in gastric and breast cancers, and a gastric cancer scoring system (GCSS) has recently been suggested. We investigated HER2 protein expression using GCSS and a breast cancer scoring system (BCSS) and correlated it with HER2 gene amplification. HER2 status was evaluated in 1091 cases by analyzing tissue microarrays constructed using 2 different cores from each case. Polyclonal (HercepTest) and monoclonal (Pathway) antibodies were used for immunohistochemistry (IHC), and results were scored by BCSS and GCSS. Gene amplification was evaluated by automated dual-color silver-enhanced in situ hybridization (SISH) in all cases and correlated with the results from fluorescence in situ hybridization (FISH) in 590 cases. The concordance between the IHC results using polyclonal and monoclonal antibodies was high (κ = 0.785). The results of dual-color SISH and FISH showed very high concordance as well (κ = 0.918). GCSS was significantly more sensitive for detecting SISH positivity than was BCSS in both antibodies (polyclonal, P =.003; monoclonal, P <.001), but specificity was higher in BCSS than GCSS (polyclonal, P =.004; monoclonal, P <.001). It has been recently shown that HER2-overexpressing patients with unresectable gastric cancer benefited from trastuzumab therapy. Because IHC is recommended before gene amplification studies in HER2 testing, GCSS should be used for evaluating HER2 expression in gastric cancers.

AB - It has been reported that HER2 expression is different in gastric and breast cancers, and a gastric cancer scoring system (GCSS) has recently been suggested. We investigated HER2 protein expression using GCSS and a breast cancer scoring system (BCSS) and correlated it with HER2 gene amplification. HER2 status was evaluated in 1091 cases by analyzing tissue microarrays constructed using 2 different cores from each case. Polyclonal (HercepTest) and monoclonal (Pathway) antibodies were used for immunohistochemistry (IHC), and results were scored by BCSS and GCSS. Gene amplification was evaluated by automated dual-color silver-enhanced in situ hybridization (SISH) in all cases and correlated with the results from fluorescence in situ hybridization (FISH) in 590 cases. The concordance between the IHC results using polyclonal and monoclonal antibodies was high (κ = 0.785). The results of dual-color SISH and FISH showed very high concordance as well (κ = 0.918). GCSS was significantly more sensitive for detecting SISH positivity than was BCSS in both antibodies (polyclonal, P =.003; monoclonal, P <.001), but specificity was higher in BCSS than GCSS (polyclonal, P =.004; monoclonal, P <.001). It has been recently shown that HER2-overexpressing patients with unresectable gastric cancer benefited from trastuzumab therapy. Because IHC is recommended before gene amplification studies in HER2 testing, GCSS should be used for evaluating HER2 expression in gastric cancers.

KW - Gastric Cancer

KW - HER2

KW - Immunohistochemistry

KW - In situ hybridization

KW - Sensitivity

KW - Specificity

UR - http://www.scopus.com/inward/record.url?scp=84857040826&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2011.05.019

DO - 10.1016/j.humpath.2011.05.019

M3 - Article

C2 - 21855114

AN - SCOPUS:84857040826

VL - 43

SP - 413

EP - 422

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 3

ER -